share_log

United Therapeutics | 10-Q: Q2 2024 Earnings Report

United Therapeutics | 10-Q: Q2 2024 Earnings Report

美國聯合醫療 | 10-Q：2024財年二季報
美股SEC公告 ·  07/31 18:34

Moomoo AI 已提取核心訊息

United Therapeutics reported Q2 2024 revenue of $714.9 million, up 20% YoY, with Tyvaso products leading growth at $398.2 million, a 25% increase. Net income rose to $298.9 million from $266.9 million in Q2 2023. Tyvaso DPI sales jumped 33% to $258.3 million, while nebulized Tyvaso grew 12% to $139.9 million.R&D expenses increased 57% to $139.6 million, reflecting higher spending on organ manufacturing projects and upfront licensing payments. The company's cash position remained strong at $4.3 billion as of June 30. United Therapeutics also completed a $1 billion accelerated share repurchase program during the quarter.Looking ahead, the company expects continued revenue growth from Tyvaso DPI adoption and expansion in pulmonary hypertension associated with interstitial lung disease (PH-ILD) patients. United Therapeutics is advancing multiple clinical programs, including phase 3 trials for nebulized Tyvaso in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The company also highlighted progress in its organ manufacturing initiatives, including xenotransplantation and 3D bioprinting technologies.
United Therapeutics reported Q2 2024 revenue of $714.9 million, up 20% YoY, with Tyvaso products leading growth at $398.2 million, a 25% increase. Net income rose to $298.9 million from $266.9 million in Q2 2023. Tyvaso DPI sales jumped 33% to $258.3 million, while nebulized Tyvaso grew 12% to $139.9 million.R&D expenses increased 57% to $139.6 million, reflecting higher spending on organ manufacturing projects and upfront licensing payments. The company's cash position remained strong at $4.3 billion as of June 30. United Therapeutics also completed a $1 billion accelerated share repurchase program during the quarter.Looking ahead, the company expects continued revenue growth from Tyvaso DPI adoption and expansion in pulmonary hypertension associated with interstitial lung disease (PH-ILD) patients. United Therapeutics is advancing multiple clinical programs, including phase 3 trials for nebulized Tyvaso in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The company also highlighted progress in its organ manufacturing initiatives, including xenotransplantation and 3D bioprinting technologies.
美國聯合醫療報告了2024年第二季度的營業收入爲71490萬美元，同比增長20%，其中Tyvaso產品以39820萬美元的銷售額領先，增長25%。凈利潤從2023年第二季度的26690萬美元上升至29890萬美元。Tyvaso DPI的銷售額躍升33%至25830萬美元，而霧化Tyvaso的銷售額增長12%至13990萬美元。研發費用增加57%至13960萬美元，反映出在器官制造項目和前期許可支付上的支出增加。截止6月30日，公司現金狀況依然強勁，達到43億美元。美國聯合醫療在這一季度還完成了一項價值10億美元的加速股票回購計劃。展望未來，公司預計在Tyvaso DPI採用和與間質性肺病（PH-ILD）患者相關的肺動脈高壓擴展方面將繼續實現營業收入增長。美國聯合醫療正在推進多個臨牀項目，包括稀有特發性肺纖維化和進行性肺纖維化的霧化Tyvaso的第三階段臨牀試驗。公司還強調了其在器官制造計劃上的進展，包括異種移植和3D生物打印技術。
美國聯合醫療報告了2024年第二季度的營業收入爲71490萬美元，同比增長20%，其中Tyvaso產品以39820萬美元的銷售額領先，增長25%。凈利潤從2023年第二季度的26690萬美元上升至29890萬美元。Tyvaso DPI的銷售額躍升33%至25830萬美元，而霧化Tyvaso的銷售額增長12%至13990萬美元。研發費用增加57%至13960萬美元，反映出在器官制造項目和前期許可支付上的支出增加。截止6月30日，公司現金狀況依然強勁，達到43億美元。美國聯合醫療在這一季度還完成了一項價值10億美元的加速股票回購計劃。展望未來，公司預計在Tyvaso DPI採用和與間質性肺病（PH-ILD）患者相關的肺動脈高壓擴展方面將繼續實現營業收入增長。美國聯合醫療正在推進多個臨牀項目，包括稀有特發性肺纖維化和進行性肺纖維化的霧化Tyvaso的第三階段臨牀試驗。公司還強調了其在器官制造計劃上的進展，包括異種移植和3D生物打印技術。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間